局部特异性IgE可预测和监测尘螨皮下免疫治疗反应
本研究纳入114例完成1年皮下免疫治疗(SCIT)的尘螨过敏性鼻炎(AR)患者,按症状改善是否超过30%分为高应答和低应答。治疗前鼻分泌物中Der p、Der f、Der p 1、Der p 2的特异性IgE(sIgE)水平及sIgE/总IgE(tIgE)比值可区分高低应答者。治疗后这些鼻分泌物sIgE水平下降与临床改善相关。鼻分泌物sIgE/tIgE比值的AUC高于血清。
要点
- 鼻分泌物sIgE及sIgE/tIgE比值可预测SCIT早期应答。
- 治疗后鼻分泌物sIgE下降与症状改善相关。
- 鼻分泌物sIgE/tIgE比值预测价值高于血清。
核心结论
- 鼻分泌物中的免疫学指标是有效预测和监测早期SCIT反应的潜在生物标志物。
研究设计与样本
- 研究纳入114例完成1年SCIT随访的尘螨过敏性鼻炎患者,按平均总联合评分(ATCS)改善是否超过30%分为高应答和低应答。
- 治疗前后测量血清和鼻分泌物中尘螨及其主要组分的免疫球蛋白水平,并进行预测指数(Pi)和治疗指数(Ti)分析及ROC曲线分析。
主要发现
- 阳性SCIT反应与较低基线年龄、较高症状评分、过敏原特异性IgE(sIgE)水平及sIgE/总IgE(tIgE)比值相关。
- Pi分析显示,治疗前鼻分泌物中Der p、Der f、Der p 1和Der p 2的sIgE水平升高及sIgE/tIgE比值较高可区分高应答与低应答者。
- Ti分析显示,治疗后这些鼻分泌物sIgE水平下降与临床结局改善相关。
- 逻辑回归显示,血清和鼻分泌物中Der p和Der f的基线sIgE/tIgE比值,以及血清中Der p 1和Der p 2的基线sIgE/tIgE比值,均与临床改善正相关。
- 鼻分泌物中Der p(0.833 vs. 0.758)和Der f(0.813 vs. 0.738)的sIgE/tIgE比值AUC值高于血清。
关键数值与推荐
- 高应答与低应答以ATCS改善>30%为界。
- 鼻分泌物Der p sIgE/tIgE比值AUC为0.833,血清为0.758。
- 鼻分泌物Der f sIgE/tIgE比值AUC为0.813,血清为0.738。
临床怎么用
- 临床可检测鼻分泌物中尘螨主要组分的sIgE及sIgE/tIgE比值,辅助预测SCIT早期应答并监测治疗反应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Identifying predictive and monitoring biomarkers for allergen immunotherapy response is crucial for enhancing clinical efficacy. This study aims to investigate the systemic and local levels of immunoglobulins and identify potential biomarkers in house dust mite (HDM) allergic rhinitis (AR) patients who are undergoing subcutaneous immunotherapy (SCIT). METHODS: This study enrolled 114 AR patients who completed 1-year SCIT follow-up. High responders and low responders were classified based on >30% improvement in the average total combined score (ATCS). Immunoglobulin levels of HDM and its major components were measured in serum and nasal secretions before and after treatment. Predictive index (Pi) and therapeutic index (Ti) analyses were performed using linear regression to assess the impact of baseline immunoglobulin concentrations and their pre- to post-treatment changes on symptom alleviation. Receiver operating characteristic (ROC) curve analysis with area under the curve (AUC) quantification was performed to evaluate predictive value for clinical responses. RESULTS: Positive SCIT response correlated with lower baseline age and higher symptom scores, allergen-specific IgE (sIgE) levels, and sIgE/total IgE (tIgE) ratio. Pi analysis revealed that elevated pre-treatment nasal sIgE levels and higher sIgE/tIgE ratios for Der p, Der f, Der p 1, and Der p 2 distinguished high from low responders. Ti analysis showed that post-treatment decreases in these nasal sIgE levels correlated with improved clinical outcomes. Logistic regression showed baseline sIgE/tIgE ratios for Der p and Der f both in serum and nasal secretions, and Der p 1 and Der p 2 in serum positively correlated with clinical improvement. The sIgE/tIgE ratios of Der p (0.833 vs. 0.758) and Der f (0.813 vs. 0.738) in nasal secretions exhibited higher AUC values compared to serum. CONCLUSIONS: Immunologic indicators in nasal secretions are potential biomarkers for the effective prediction and monitoring of early SCIT responses.
引用
- Xu X, Li J, Zhang X, et al. Local Specific IgE Levels Can Predict and Monitor the Therapeutic Response to Subcutaneous Immunotherapy With House Dust Mite. Int Forum Allergy Rhinol. 2026. PMID: 41532683. doi:10.1002/alr.70098
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。